FDA approval may dampen controversy over a high-priced drug - STAT

FDA approval may dampen controversy over a high-priced drug  STAT

The approval potentially adds unforeseen competition for Catalyst Pharmaceuticals, which last winter won FDA approval to market a pricey drug for adults.

(CLICK HERE TO READ AND SEE MORE)